# EDGAR Filing Document

**Accession Number:** 0001840056
**File Stem:** 0001439222-26-000038
**Filing Date:** 2026-3
**Character Count:** 9613
**Document Hash:** b1e14186281f9e423f4da3bc17c7401b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001439222-26-000038.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0001439222-26-000038

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260301

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Jones Cecilia
- **CENTRAL INDEX KEY:** 0001840056

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36014
- **FILM NUMBER:** 26714317

**MAIL ADDRESS:**
- **STREET 1:** C/O AGIOS THERAPEUTICS, INC.
- **STREET 2:** 88 SIDNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AGIOS PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001439222
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 88 SIDNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-649-8600

**MAIL ADDRESS:**
- **STREET 1:** 88 SIDNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AGIOS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20080703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Jones Cecilia<br><sub>(Last) (First) (Middle)</sub><br>C/O AGIOS PHARMACEUTICALS, INC.<br>88 SIDNEY STREET<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02139<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>AGIOS PHARMACEUTICALS, INC. [ AGIO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common stock | 2026-03-02 |  | M |  | 2000 | A | $0 | 39394 | D |  |
| Common stock | 2026-03-02 |  | S<sup>(1)</sup> |  | 594 | D | $28.96 | 38800 | D |  |
| Common stock | 2026-03-02 |  | M |  | 5666 | A | $0 | 44466 | D |  |
| Common stock | 2026-03-02 |  | S<sup>(2)</sup> |  | 1681 | D | $28.96 | 42785 | D |  |
| Common stock | 2026-03-02 |  | M |  | 4000 | A | $0 | 46785 | D |  |
| Common stock | 2026-03-02 |  | S<sup>(3)</sup> |  | 1187 | D | $28.96 | 45598 | D |  |
| Common stock | 2026-03-02 |  | M |  | 5303 | A | $0 | 50901 | D |  |
| Common stock | 2026-03-02 |  | S<sup>(3)</sup> |  | 1573 | D | $28.96 | 49328 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted stock units | <sup>(4)</sup> | 2026-03-01 |  | A |  | 14000 |  | <sup>(5)</sup> | <sup>(5)</sup> | Common stock | 14000 | $0 | 14000 | D |  |
| Stock options (right to buy) | $30.23 | 2026-03-01 |  | A |  | 52000 |  | <sup>(6)</sup> | 2036-03-01 | Common stock | 52000 | $0 | 52000 | D |  |
| Restricted stock units | <sup>(4)</sup> | 2026-03-02 |  | M |  |  | 2000 | <sup>(7)</sup> | <sup>(7)</sup> | Common stock | 2000 | $0 | 0 | D |  |
| Restricted stock units | <sup>(4)</sup> | 2026-03-02 |  | M |  |  | 5666 | <sup>(8)</sup> | <sup>(8)</sup> | Common stock | 5666 | $0 | 5667 | D |  |
| Restricted stock units | <sup>(4)</sup> | 2026-03-02 |  | M |  |  | 4000 | <sup>(9)</sup> | <sup>(9)</sup> | Common stock | 4000 | $0 | 8000 | D |  |
| Restricted stock units | <sup>(4)</sup> | 2026-03-02 |  | M |  |  | 5303 | <sup>(9)</sup> | <sup>(9)</sup> | Common stock | 5303 | $0 | 10607 | D |  |

---

### Footnotes:

(1) Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.

(2) Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.

(3) Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025.

(4) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

(5) The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.

(6) This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.

(7) The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.

(8) The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.

(9) The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.

**Signature:** /s/ William Cook, as attorney-in-fact for Cecilia Jones  
**Date:** 2026-03-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**